AstraZeneca PLC’s PI3Kα inhibitor Truqap (capivasertib) won US Food and Drug Administration approval late last year and has quickly become the standard of care in certain patients with breast cancer, but could soon face a challenger in the form of Relay Therapeutics, Inc.’s RLY-2608, which has shown strong results in a Phase I clinical trial.
Cambridge, MA-based Relay announced interim results on 9 September from the study of RLY-2608 – an allosteric, pan-mutant and isoform-selective PI3Kα inhibitor – in patients with PI3Kα-mutated, HR+ and HER2- locally advanced or metastatic breast cancer, combined with the estrogen receptor antagonist fulvestrant
Key Takeaways
-
Relay Therapeutics announced positive interim data for RLY-2608 in PI3Kα-mutated, HR+ and HER2- breast cancer, including a four-month PFS edge over the standard of care.
-
The biotech plans to meet with the FDA to discuss plans for a Phase III pivotal trial testing its drug over AstraZeneca’s Truqap
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
